

European Journal of Pharmacology

The EUROPEAN JOURNAL OF PHARMACOLOGY publishes full-length papers, short communications and rapid communications on the mechanisms of action of chemical substances affecting biological systems. The journal also considers short reviews (not exceeding 12 pages in print) intended to debate recent advances in rapidly developing fields that are within its scope.

Full length papers and short communications are grouped under the following headings: Molecular and cellular pharmacology, Neuropharmacology and analgesia, Behavioural pharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Immunopharmacology and inflammation, and Endocrine pharmacology.

Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editor review, (2) they have not been and will not be published in whole or in part in any other journal and (3) recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to. The European Journal of Pharmacology will, therefore, only consider manuscripts that describe experimenets which have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that protocol complies with the particular recommendation and that approval of their protocols was obtained.

Abridged ‘General instructions’ for authors are published at the end of each issue. Essential detailed instructions will be found in the ‘Notice to authors’, published once yearly (for 2002, in Vol. 438, Nos. 1–2, pages v–x).

Founded in 1967. Founding editors: David de Wied and Jacques van Rossum.

Editors: W.H. GISPEN, Utrecht (chairman) J. BRUINVELS, Utrecht F.P. NIJKAMP, Utrecht D.H.G. VERSTEEG, Utrecht

Honorary editor: D. DE WIED

Editorial board:

C. ADVENIER, Paris	D.A. KHARKEVICH, Moscow	J.P. PIN, Montpellier
K. AKTORIES, Freiburg im Breisgau	Z. KLEINROK, Lublin	R. QUIRION, Verdun
L. BARTHÓ, Pécs	M. LAZDUNSKI, Valbonne	J.A. RIBEIRO, Lisbon
G. BIGGIO, Cagliari	R. LEFEBVRE, Gent	P.J. ROBINSON, Newcastle
D.S. BREDT, San Francisco	X.Y. LI, Shanghai	A. SARIA, Innsbruck
O.E. BRODDE, Halle	M.J. LOHSE, Würzburg	P.R. SAXENA, Rotterdam
H. BULT, Wilrijk	W. LÖSCHER, Hannover	A. SCHOUSBOE, Copenhagen
F. CATTABENI, Milan	J. McCULLOCH, Edinburgh	R. SCHULZ, München
M.G. DARLISON, Nottingham	D.N. MIDDLEMISS, Harlow	P. SKOLNICK, Hackensack
M. ENDOH, Yamagata	K.P. MINNEMAN, Atlanta	J.C. STOCLET, Strasbourg
J.A. GARCÍA-SÁINZ, Mexico City	H. MÖHLER, Zürich	D.J. TRIGGLE, Buffalo
G.F. GEBHART, Iowa City	F. MORONI, Florence	B.J.R. WHITTLE, London
M. HAMON, Paris	S. NAHORSKI, Leicester	J. WIKBERG, Uppsala
D. HOYER, Basel	D.G. NICHOLLS, Dundee	R.J. WINQUIST, Ridgefield
E.C. HULME, London	J.M. PFEILSCHIFTER, Frankfurt	

Consultants:

B. AHRÉN, Lund; E. BEUBLER, Graz; J. BOCKAERT, Montpellier; R. BUSSE, Frankfurt/M; S.J. COOPER, Liverpool; R. COUTURE, Montreal; J.M. CRAWLEY, Bethesda; G. DI CHIARA, Cagliari; H.N. DOODS, Biberach; G.J. DUSTING, Parkville; A.W. FORD-HUTCHINSON, West Point; B.B. FREDHOLM, Stockholm; J.F. GIUDICELLI, Le Kremlin-Bicêtre; A.R. GREEN, London; R.J. GRYGLEWSKI, Kraków; A. HERMAN, Antwerpen; P. HOLZER, Graz; J.P. HUIDOBRO-TORO, Santiago; K.H. JAKOBS, Essen; H. KARAKI, Tokyo; B.E. LEONARD, Galway; B.R. LUCCHESI, Ann Arbor; C.A. MAGGI, Florence; M.J. MILLAN, Croissy-sur-Seine; R.J. MILLER, Chicago; T. NABESHIMA, Nagoya; D.J. NUTT, Bristol; M. OTSUKA, Tokyo; J.M. PALACIOS, Barcelona; J.N. PENNEFATHER, Parkville; M. RAITERI, Genova; U. RAVENS, Essen; B.P. ROQUES, Paris; H. SCHOEMAKER, Bagneux; K. SCHRÖR, Düsseldorf; K.F. SEWING, Hannover; K. STARKE, Freiburg im Breisgau; J. ZAAGSMA, Groningen

Contents continued

Pharmacological profile of MEN91507, a new CysLT₁ receptor antagonist	ERRATUM	
F. Cabre, A. Carabaza, A.M. Garcia, L. Calvo, P. Cucchi, A. Palomer, J. Pascual, M.L. Garcia, S. Manzini, A. Lecci, A. Crea and C.A. Maggi	Erratum on contents page of EJP 444/1-2	335
Anti-inflammatory potency of FR167653, a p38 mitogen-activated protein kinase inhibitor, in mouse models of acute inflammation	<i>Author index</i>	337
T. Nishikori, K. Irie, T. Suganuma, M. Ozaki and T. Yoshioka	<i>Keyword index</i>	341

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to: ADONIS B.V., P.O. Box 993, 1000 AZ Amsterdam, The Netherlands. Or you can contact ADONIS by e-mail: info@adonis.nl or visit the website at www.adonis.nl

Advertising information: Advertising orders and enquiries can be sent to: **USA, Canada and South America:** Mr Tino DeCarlo, The Advertising Department, Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: t.decarlo@elsevier.com. **Japan:** The Advertising Department, Elsevier Science K.K., 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047. **Europe and ROW:** Commercial Sales Department, Elsevier Science Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 1865 843016; fax: (+44) 1865 843976; e-mail: media@elsevier.com

USA mailing notice: *European Journal of Pharmacology* (0014-2999) is published weekly by Elsevier Science B.V. (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA is US\$8402.00 (valid in North, Central and South America), including air speed delivery. Periodicals postage paid at Jamaica, NY 11431.

USA POSTMASTER: Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Ave, Elmont, NY 11003.

AIRFREIGHT AND MAILING in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.

Printed in The Netherlands